Cardiff Oncology
CRDF
91 hedge funds and large institutions have $41M invested in Cardiff Oncology in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 34 reducing their positions, and 14 closing their positions.
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
5% more funds holding
Funds holding: 87 → 91 (+4)
14.32% less ownership
Funds ownership: 52.48% → 38.16% (-14%)
26% less call options, than puts
Call options by funds: $348K | Put options by funds: $468K
41% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 34
69% less capital invested
Capital invested by funds: $132M → $41M (-$91.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.74M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.55M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.17M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.15M |
| 5 |
EGM
Engineers Gate Manager
New York
|
+$869K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$15.2M |
| 2 |
Janus Henderson Group
London,
|
-$6.3M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$5.91M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.02M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.02M |
CRDF Hedge Fund Activity: Q1 2022 in Review
91 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2022, worth a combined $41M — down 69% from $132M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CRDF positions and 14 closed out — a net gain of 4 holders — while 20 added to existing stakes and 34 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.74M. The largest seller was Caxton Corporation, exiting entirely with an estimated $15.2M sold.
- 91 institutional investors held Cardiff Oncology (CRDF) as of Q1 2022, up from 87 in Q4 2021.
- Funds reported $41M of Cardiff Oncology stock for Q1 2022, down 69% quarter-over-quarter.
- 18 funds opened new Cardiff Oncology positions in Q1 2022 and 14 closed out, a net change of +4 holders.
- The largest Cardiff Oncology buyer in Q1 2022 was Renaissance Technologies, an estimated $1.74M added.
- The largest Cardiff Oncology seller in Q1 2022 was Caxton Corporation, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2022.